Simone Ummarino
Staff Scientist II
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Year:
2026
Year:
2026
Year:
2025
Advancements in genome sequencing technologies have uncovered the multifaceted roles of long non-coding RNAs (lncRNAs) in human cells. Recent discoveries have identified lncRNAs as major players in gene regulatory pathways, highlighting their pivotal role in human cell growth and development. Their dysregulation is implicated in the onset of genetic disorders and age-related diseases, including cancer. Specifically, they have been found to orchestrate molecular mechanisms impacting epigenetics, including DNA methylation and hydroxymethylation, histone modifications, and chromatin remodeling, thereby significantly influencing gene expression. This review provides an overview of the current knowledge on lncRNA-mediated epigenetic regulation of gene expression, emphasizing the biomedical implications of lncRNAs in the development of different types of cancers and genetic diseases.
Year:
2025
Small activating RNAs are short double-stranded RNAs designed to upregulate transcription of target genes. By this virtue, they can be used to restore expression of genes frequently silenced in cancer. AW1-51 (also referred to as CEBPA-51), the first small activating RNA therapeutic to enter clinical evaluation, has demonstrated biological activity and safety in Phase II trials for hepatocellular carcinoma, both as monotherapy and in combination with sorafenib, and in Phase 1a/1b in combination with pembrolizumab for patients with advanced solid tumors. It targets the master regulator CCAAT enhancer-binding protein alpha, abnormally silenced by DNA methylation in a wide range of hematological and non-hematological malignancies. However, the molecular events enabling this mechanism are only partially elucidated. In this study, we uncovered the molecular basis for AW1-51-induced transcriptional reactivation of CCAAT enhancer-binding protein alpha demonstrating that by directly promoting DNA demethylation of its promoter restores its expression, protein synthesis, and consequently cell differentiation. These findings unveil AW1-51 as a prototype for RNA-based precision medicine enabling conditional expression of CCAAT enhancer-binding protein alpha in diseases characterized by aberrant gene silencing and extending its potential therapeutic impact beyond cancer.
Year:
2025
Year:
2023
Collaborators (11)
Alexander Ebralidze
Staff Scientist II
Beth Israel Deaconess Medical Center
Angela Di Baldassarre
Head, Reprogramming and Cell Differentiation Laboratory Center for Advanced Studies and Technology
University of Chieti-Pescara
Annalisa Di Ruscio
University of Eastern Piedmont
Susumu Kobayashi
Beth Israel Deaconess Medical Center
pedro p. medina
Head of Research Group
Universidad de Granada
Miwako Kakiuchi
The Univeristy of Tokyo
Daniel G. Tenen
Harvard University
Hiroko Oda
University of Tokyo
Nagy HABIB
Imperial College London
Madhura Deshpande
Assistant Professor of Research in Reproductive medicine & Obstetrics and Gynecology
Weill Cornell Medicine
barbara ghinassi
Professore Associato
University of Chieti-Pescara
Make your next move.
Prepare your application
Review drafts before you send them.